| In partnership with |  |
| Good day, 360! | Here are some of our top movers today. And don't forget to join us in Market Masters - the hottest trading room around 🔥. Be the best prepared trader on the Street! | | FOCUS LIST🔎 | SES - Up over 40% in pre after announcing collaboration with NVIDIA, Crusoe, and Supermicro on AI for Science initiative to accelerate material discovery in electric transportation | VIGL - Up over 6% in pre after announcing FDA has removed partial clinical hold on VG-3927 | ACIU - Up over 7% in pre after announcing it has received second milestone payment following progress in Phase 2b ReTain Trial of ACI-35.030 in preclinical Alzheimer's disease | | *Sponsored by 1440 Media | The Daily Newsletter for Intellectually Curious Readers | | We scour 100+ sources daily Read by CEOs, scientists, business owners and more 3.5 million subscribers
| Sign up today! |
|
| | HOTLIST🔥 | SES - Up over 40% in pre after announcing collaboration with NVIDIA, Crusoe, and Supermicro on AI for Science initiative to accelerate material discovery in electric transportation | SES AI Corporation (SES) engages in the development and production of high-performance Lithium-metal rechargeable batteries for electric vehicles, electric vehicle take-off and landing, and other applications. | In the pre-market this morning, the company announced a groundbreaking initiative to accelerate material discovery in electric transportation. | By mapping the universe of small molecules using a cutting-edge supercomputer optimized for artificial intelligence ("AI"), this pioneering project aims to revolutionize the understanding of battery chemistry, enhance energy storage solutions, and advance energy efficient technology. | The initiative will leverage Crusoe's innovative and purpose-built AI cloud platform, powered by NVIDIA and Supermicro, showcasing a unique collaboration at the intersection of science, computing, and sustainable computing. | The stock traded up over 40% in the pre-market in reaction to the news. | | The first target for bulls is the prior support area at $1.36 which now becomes potential resistance. | Above it, targets to the upside are $1.44, $1.53 and then the pre-market high at $1.60. Beyond that, $1.70 and $1.85 come into play. | Below $1.36, targets to the downside are $1.26, $1.20, $1.10 and then a gap fill at $1.02. | | VIGL - Up over 6% in pre after announcing FDA has removed partial clinical hold on VG-3927 | Vigil Neuroscience Inc. (VIGL) is a clinical-stage biotechnology company that focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. | In the pre-market this morning, the company announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its ongoing Phase 1 clinical trial of VG-3927. The FDA's decision was based on a complete response submitted by the Company. | Petra Kaufmann, M.D., F.A.A.N., Chief Medical Officer at Vigil stated: "While the partial clinical hold did not delay clinical development of VG-3927, the option to increase the exposure limit provides us the best opportunity to explore the full pharmacology of VG-3927 as a potentially novel, next generation therapy for those living with Alzheimer's disease." | The stock traded up over 6% in the pre-market in reaction to the news. | | The $3.80 area acted as support in the pre-market and now becomes a potential resistance level. | Above it, targets to the upside are $4, $4.20 and then the pre-market high at $4.53. Beyond that, $4.80 and $5 come into play. | Below $3.80, targets to the downside are a gap fill at $3.57 and then $3.40. | | Small Accounts Challenge!!! | Last Week's Performance… | *$2,000 - $28,175 or 1,309% |  | *Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
| Get the Blueprint Today! |
|
| | ACIU - Up over 7% in pre after announcing it has received second milestone payment following progress in Phase 2b ReTain Trial of ACI-35.030 in preclinical Alzheimer's disease | AC Immune SA (ACIU) is a clinical stage biopharmaceutical company that discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. | In the pre-market this morning the company announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company. | The milestone payment has been triggered by the rapid rate of prescreening in the potentially registrational Phase 2b ReTain trial investigating active-immunotherapy candidate ACI-35.030 (now called "JNJ-2056") to treat preclinical (pre-symptomatic) Alzheimer's disease (AD). | With last December's milestone payment, this brings the total milestone payments received for ACI-35.030 related to this trial to CHF 40 million. | The stock traded up over 7% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $3.55. | Above it, targets to the upside are $3.70, $4 and $4.20. | Below $3.55, targets to the downside are $3.40 and then a gap fill at $3.27 with $3.05 below that. | | MARKET NEWS 📰 | | | P.S. Make sure you text "RAGE" to (888) 404-5747 to get all of our latest HOT STOCK ideas! | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Tidak ada komentar:
Posting Komentar